Long-term administration of gamma interferon is effective for the control of patients with severe atopic dermatitis, according to the results of an open-label Phase II study involving 40 patients. The data were presented at the Clinical Dermatology 2000 meeting in Vancouver, Canada, on May 31.
Connective Therapeutics, which is developing gamma interferon for atopic dermatitis under license from Genentech, said that the long-term data reinforce previous Phase II results from a 12-week study published in the Journal of the American Academy of Dermatology.
In the new trial, 24 patients had completed one year of therapy while 16 had completed two years. Total body area involvement in the one-year group was 56% at baseline, which reduced to 21%. For the two-year group, the respective values were 60% and 36%. Side effects were minimal, and a Phase II trial is planned.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze